Corp-Ethics.com - Report: Glaxo drops appeal in Aids drug pricing case

Company	GlaxoSmithKline [Company Info]
	Track this Company (an email will be sent to you everytime a report is filed about this company)

Date	Issue	Title
22nd Sep 2004	Questionable Practice	Glaxo drops appeal in Aids drug pricing case

Report

A landmark legal complaint against British drug maker GlaxoSmithKline (GSK) over its Aids drug pricing and policies in South Africa will proceed after GSK dropped its public and repeated vows to appeal a decision allowing the case to go forward, according to AidsHealthcare Foundation (AHF).

Instead, GSK simply filed a required legal response to the complaint, AHF said.

The complaint was filed with South Africa's Competition Tribunal in August by AHF, the US' largest Aids organisation and several other South African Aids advocates.
AHF operates the 'Ithembalabantu' (Zulu for people's hope) clinic, a free Aids treatment clinic in Umlazi Township, KwaZulu Natal in partnership with the Network of Aids Communities of South Africa (NetCom SA) a local non-government organisation.

In the complaint, AHF and others allege that GSK has charged excessive prices for Aids drugs to the detriment of South Africans with HIV/Aids and in violation of the Competition Act.

The complaint was originally filed with the Competition Commission in January 2003.

The Treatment Action Campaign (TAC) had lodged a similar complaint with the Competition Commission against GSK during 2002.

The Competition Commission initially decided to refer that complaint, as well as the AHF complaint, to the Competition Tribunal. During December 2003, TAC and GSK concluded a settlement endorsed by the Competition Commission.

However, AHF was not a party to that settlement.

Earlier this year, the Competition Tribunal of South Africa agreed to hear the complaint, which was filed by individual South Africans and AHF.

The Tribunal also ordered GSK to pay AHF's legal costs.

Other Reports on GlaxoSmithKline
Date	Issue	Company	Report
29th Jan 2007	Questionable Practice	GlaxoSmithKline	GSK hid paxil suicide link
10th Aug 2006	Other Issue	GlaxoSmithKline	Glaxo pays $70m to end price row
29th Mar 2006	Questionable Practice	GlaxoSmithKline	Glaxo agrees US Paxil settlement
18th Mar 2005	Other Issue	GlaxoSmithKline	Glaxo shares dip on factory probe
6th Sep 2004	Other Issue	GlaxoSmithKline	GSK faces anti-depressant lawsuit
19th May 2004	Other Issue	GlaxoSmithKline	New York sues GlaxoSmithKline
11th May 2004	Fraud Investigation	GlaxoSmithKline	GlaxoSmithKline faces antitrust investigation
22nd Jan 2004	Fraud Investigation	GlaxoSmithKline	$11.1 Million settlement
8th Jan 2004	Questionable Practice	GlaxoSmithKline	£1.5bn Tax Bill
16th Dec 2003	Questionable Practice	GlaxoSmithKline	Glaxo's CEO to scoop 5.7 mln stg a year
25th Jun 2003	Questionable Practice	GlaxoSmithKline	FDA tells Glaxo to pull misleading Flonase ads
25th Jun 2003	Questionable Practice	GlaxoSmithKline	Ordered to pull misleading adverts

Related Reports from the Pharamaceutical Industry
Company	Issue	Report
Merck	Other Issue	Vioxx court case ends in mistrial
Merck	Other Issue	Vioxx drug ban hits Merck profits
Pfizer	Other Issue	Nigeria files new Pfizer claims
Bristol-Myers Squibb	Fraud Investigation	Drug bosses face civil fraud suit
Pfizer	Other Issue	Watchdog probes drug distribution